摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl (3R,4S)-4-hydroxy-3-phenylpiperidine-1-carboxylate | 880094-01-9

中文名称
——
中文别名
——
英文名称
tert-butyl (3R,4S)-4-hydroxy-3-phenylpiperidine-1-carboxylate
英文别名
(3R,4S)-4-hydroxy-3-phenyl-1-piperidinecarboxylic acid tert-butyl ester;tert-Butyl (3R*,4S*)-4-hydroxy-3-phenylpiperidine-1-carboxylate
tert-butyl (3R,4S)-4-hydroxy-3-phenylpiperidine-1-carboxylate化学式
CAS
880094-01-9
化学式
C16H23NO3
mdl
——
分子量
277.364
InChiKey
DISTZHMQLVYZLN-KBPBESRZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • NK1 and NK3 antagonists
    申请人:O'Neill T. Brian
    公开号:US20050256164A1
    公开(公告)日:2005-11-17
    The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.
    这项发明涉及一种具有神经激肽抑制性能的化合物,包括该化合物的药物组合物以及用于神经激肽介导疾病的治疗方法。
  • Piperidine derivative, process for producing the same, and use
    申请人:Ikeura Yoshinori
    公开号:US20060167052A1
    公开(公告)日:2006-07-27
    The present invention provides a compound represented by the formula: wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R 1 is a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group or an optionally substituted heterocyclic group, X is an oxygen atom or an optionally lo substituted imino group, Z is an optionally substituted methylene group, Ring A is an optionally further substituted piperidine ring, and Ring B is an optionally substituted aromatic ring, provided that when Z is a methylene group substituted with an oxo group, R 1 is not a methyl group, and 15 when Z is a methylene group substituted with a methyl group, Ring B is a substituted aromatic ring, or a salt thereof, which is a novel piperidine derivative having excellent antagonistic action for a tachykinin receptor and useful as a medicament, particularly an agent for preventing and/or treating urinary frequency and/or urinary incontinence.
    本发明提供了一种化合物,其表示为以下式子:其中Ar是芳基、芳基烷基或芳香杂环基,每个基团都可以被取代,R1是氢原子、可选取代的碳氢基团、酰基或可选取代的杂环基团,X是氧原子或可选取代的亚胺基团,Z是可选取代的亚甲基团,环A是可选进一步取代的哌啶环,环B是可选取代的芳香环,但当Z是取代有氧基的亚甲基团时,R1不是甲基基团,而当Z是取代有甲基基团的亚甲基团时,环B是取代的芳香环,或其盐。该化合物是一种新型哌啶衍生物,具有优异的缓解速激肽受体拮抗作用,可用作药物,特别是用作预防和/或治疗尿频和/或尿失禁的药剂。
  • PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP1553084A1
    公开(公告)日:2005-07-13
    The present invention provides a compound represented by the formula:    wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R1 is a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group or an optionally substituted heterocyclic group, X is an oxygen atom or an optionally substituted imino group, Z is an optionally substituted methylene group, Ring A is an optionally further substituted piperidine ring, and Ring B is an optionally substituted aromatic ring, provided that when Z is a methylene group substituted with an oxo group, R1 is not a methyl group, and when Z is a methylene group substituted with a methyl group, Ring B is a substituted aromatic ring, or a salt thereof, which is a novel piperidine derivative having excellent antagonistic action for a tachykinin receptor and useful as a medicament, particularly an agent for preventing and/or treating urinary frequency and/or urinary incontinence.
    本发明提供了一种由式表示的化合物: 其中 Ar 是芳基、芳烷基或芳香杂环基团,每个基团均可被取代;R1 是氢原子、任选取代的烃基、酰基或任选取代的杂环基团;X 是氧原子或任选取代的亚氨基;Z 是任选取代的亚甲基;环 A 是任选进一步取代的哌啶环;环 B 是任选取代的芳香环、当 Z 是被氧代基团取代的亚甲基时,R1 不是甲基;当 Z 是被甲基取代的亚甲基时,环 B 是被取代的芳香环,或其盐,这是一种新型哌啶衍生物,对快速激肽受体有很好的拮抗作用,可用作药物,特别是预防和/或治疗尿频和/或尿失禁的药物。
  • PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS
    申请人:Pfizer Products Inc.
    公开号:EP1748984A1
    公开(公告)日:2007-02-07
  • US7622487B2
    申请人:——
    公开号:US7622487B2
    公开(公告)日:2009-11-24
查看更多